Chris Behrenbruch

Chris Behrenbruch

Company: Telix Pharmaceuticals

Job title: CEO


Bringing Radiopharmaceuticals to Mainstream Oncology – The “Combo” 1:30 pm

Therapeutic nuclear medicine has traditionally sat at the periphery of mainstream oncology. In order for “theranostics” to gain traction they will need to integrate Evaluate the multiple strategies that exist for both diagnostic and therapeutic radiopharmaceuticals for them to augment and complement standard of care Oncology standard care is complex and moving quickly, particularly in…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.